Global Multiple Sclerosis Market, Patient Numbers & Forecast (By Mode of Administration: Injectables Market, Infusions Market, Orals Market) – Actual & Unmet (Potential)

September 2017 | | ID: GF0EC3C3B42EN
Renub Research

Abstracts

Global Multiple Sclerosis Market, Patient Numbers & Forecast (By Mode of Administration: Injectables Market, Infusions Market, Orals Market) – Actual & Unmet (Potential) published by Renub Research on Multiple Sclerosis Market. This 108 page report with 93 figures and 1 Tables provides 6 Countries: actual and potential/unmet patient numbers and market. This report also explains multiple sclerosis disease modifying therapy (DMT) mode of administration.

• Actual Market is the current market which is already present
• Unmet Market is the market which can be accomplished; but it has yet not been accomplished due to demand and supply gap. At present DMT receiving patients are less than total number of multiple sclerosis patient numbers.

6 Countries Multiple Sclerosis Market & Patients Treated Studied in the Report is as Follows:

1. United States
2. United Kingdom
3. Germany
4. France
5. Italy
6. Spain

Worldwide and United States Multiple Sclerosis Market & Patients Treated by Mode of administration

1. Injectables
2. Infusions
3. Orals

Key Questions Answered in the Report?

• What is multiple sclerosis market globally and its growth potential in Future?
• How many number of patients treated by disease modifying therapy globally?
• What is the multiple sclerosis market in United States and other European countries?
• How many number of multiple sclerosis patients living in United States and other European countries?

Contents

1 RESEARCH FINDINGS

2 GLOBAL MULTIPLE SCLEROSIS PATIENT NUMBERS (2011 – 2022)

2.1 Patient Number & Forecast
2.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
2.3 By Mode of Administration – Injectables, Infusion, Oral Patient Numbers & Forecast
  2.3.1 Injectables
  2.3.2 Infusions
  2.3.3 Orals

3 GLOBAL MULTIPLE SCLEROSIS MARKET (2011 – 2022)

3.1 Unmet Market & Forecast
3.2 Market & Forecast
3.3 By Mode of Administration - Injectables, Infusions, Orals Market & Forecast
  3.3.1 Injectables Market
  3.3.2 Infusions Market
  3.3.3 Orals Market

4 PATIENT SHARE – GLOBAL MULTIPLE SCLEROSIS (2011 – 2022)

4.1 Patient Numbers Share & Forecast – (UK, France, Germany, Italy, Spain & United States)
4.2 Disease-Modifying Therapy (DMT) – (UK, France, Germany, Italy, Spain & United States)
4.3 By Mode of Administration – Injectables, Infusion, Oral

5 MARKET SHARE – GLOBAL MULTIPLE SCLEROSIS (2011 – 2022)

5.1 Unmet Market Share & Forecast – (UK, France, Germany, Italy, Spain & United States)
5.2 Market Share & Forecast – (UK, France, Germany, Italy, Spain & United States)
5.3 By Mode of Administration – Injectables, Infusion, Oral

6 UNITED KINGDOM

6.1 Multiple Sclerosis Patient Numbers (2011 – 2022)
  6.1.1 Patient Number & Forecast
  6.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
6.2 Multiple Sclerosis Market (2011 – 2022)
  6.2.1 Unmet Market & Forecast
  6.2.2 Market & Forecast

7 FRANCE

7.1 Multiple Sclerosis Patient Number (2011 – 2022)
  7.1.1 Patient Number & Forecast
  7.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
7.2 Multiple Sclerosis Market (2011 – 2022)
  7.2.1 Unmet Market & Forecast
  7.2.2 Market & Forecast

8 GERMANY

8.1 Multiple Sclerosis Patient Number (2011 – 2022)
  8.1.1 Patient Number & Forecast
  8.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
8.2 Multiple Sclerosis Market (2011 – 2022)
  8.2.1 Unmet Market & Forecast
  8.2.2 Market & Forecast

9 ITALY

9.1 Multiple Sclerosis Patient Number (2011 – 2022)
  9.1.1 Patient Number & Forecast
  9.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
9.2 Multiple Sclerosis Market (2011 – 2022)
  9.2.1 Unmet Market & Forecast
  9.2.2 Market & Forecast

10 SPAIN

10.1 Multiple Sclerosis Patient Number (2011 – 2022)
  10.1.1 Patient Number & Forecast
  10.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
10.2 Multiple Sclerosis Market (2011 – 2022)
  10.2.1 Unmet Market & Forecast
  10.2.2 Market & Forecast

11 UNITED STATES

11.1 Multiple Sclerosis Patient Numbers (2011 – 2022)
  11.1.1 Patient Number & Forecast
  11.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
11.2 By Mode of Administration
  11.2.1 Injectables Patients Numbers
  11.2.2 Infusions Patients Numbers
  11.2.3 Orals Patient Numbers
11.3 United States Multiple Sclerosis Market (2011 – 2022)
  11.3.1 Unmet Market & Forecast
  11.3.2 Market & Forecast
11.4 By Mode of Administration
  11.4.1 Injectables Market
  11.4.2 Infusions Market
  11.4.3 Orals Market

12 GROWTH DRIVERS (DUE TO DATA CONFIDENTIALITY, GROWTH FACTORS HAVE NOT BEEN DISCLOSED IN THIS TABLE OF CONTENTS)

12.1 Point no.
12.2 Point no.

13 CHALLENGES (DUE TO DATA CONFIDENTIALITY, CHALLENGES HAVE NOT BEEN DISCLOSED IN THIS TABLE OF CONTENTS)

13.1 Point no.
13.2 Point no.
13.3 Point no.

14 APPENDIX

List Of Figures

LIST OF FIGURES

Figure 2-1: Global - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
Figure 2-2: Global – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
Figure 2-3: Global - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
Figure 2-4: Global – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
Figure 2-5: Global – Multiple Sclerosis Injectables Patient Numbers (Thousand), 2011 – 2016
Figure 2-6: Global – Forecast for Multiple Sclerosis Injectables Patient Numbers (Thousand), 2017 – 2022
Figure 2-7: Global - Multiple Sclerosis Infusions Patient Numbers (Thousand), 2011 – 2016
Figure 2-8: Global – Forecast for Multiple Sclerosis Infusions Patient Numbers (Thousand), 2017 – 2022
Figure 2-9: Global - Multiple Sclerosis Orals Patient Numbers (Thousand), 2011 – 2016
Figure 2-10: Global – Forecast for Multiple Sclerosis Orals Patient Numbers (Thousand), 2017 – 2022
Figure 3-1: Global – Multiple Sclerosis Unmet Market (Billion US$), 2011 – 2016
Figure 3-2: Global – Forecast for Multiple Sclerosis Unmet Market (Billion US$), 2017 – 2022
Figure 3-3: Global – Multiple Sclerosis Market (Billion US$), 2011 – 2016
Figure 3-4: Global – Forecast for Multiple Sclerosis Market (Billion US$), 2017 – 2022
Figure 3-5: Global – Multiple Sclerosis Injectables Market (Million US$), 2011 – 2016
Figure 3-6: Global – Forecast for Multiple Sclerosis Injectables Market (Million US$), 2017 – 2022
Figure 3-7: Global – Multiple Sclerosis Infusions Market (Million US$), 2011 – 2016
Figure 3-8: Global – Forecast for Multiple Sclerosis Infusions Market (Million US$), 2017 – 2022
Figure 3-9: Global – Multiple Sclerosis Orals Market (Million US$), 2011 – 2016
Figure 3-10: Global – Forecast for Multiple Sclerosis Orals Market (Million US$), 2017 – 2022
Figure 4-1: Global - Patient Numbers Share (Percent), 2011 – 2016
Figure 4-2: Global – Forecast for Patient Numbers Share (Percent), 2017 – 2022
Figure 4-3: Global - Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2011 – 2016
Figure 4-4: Global – Forecast for Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2017 – 2022
Figure 4-5: Global – Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2011 – 2016
Figure 4-6: Global – Forecast for Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2017 – 2022
Figure 4-7: Global – Multiple Sclerosis Unmet Market Share (Percent), 2011 – 2016
Figure 4-8: Global – Forecast for Multiple Sclerosis Unmet Market Share (Percent), 2017 – 2022
Figure 4-9: Global – Multiple Sclerosis Market Share (Percent), 2011 – 2016
Figure 4-10: Global – Forecast for Multiple Sclerosis Market Share (Percent), 2017 – 2022
Figure 4-11: Global – Multiple Sclerosis Market by Mode of Administration Share (Percent), 2011 – 2016
Figure 4-12: Global – Forecast for Multiple Sclerosis Market by Mode of Administration Share (Percent), 2017 – 2022
Figure 5-1: United Kingdom – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 5-2: United Kingdom – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 5-3: United Kingdom – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 5-4: United Kingdom – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 5-5: United Kingdom – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 5-6: United Kingdom – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 5-7: United Kingdom – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 5-8: United Kingdom – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 6-1: France – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 6-2: France – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 6-3: France – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 6-4: France – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 6-5: France – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 6-6: France – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 6-7: France – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 6-8: France – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 7-1: Germany – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 7-2: Germany – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 7-3: Germany – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 7-4: Germany – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 7-5: Germany – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 7-6: Germany – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 7-7: Germany – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 7-8: Germany – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 8-1: Italy – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 8-2: Italy – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 8-3: Italy – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 8-4: Italy – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 8-5: Italy – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 8-6: Italy – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 8-7: Italy – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 8-8: Italy – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 9-1: Spain – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 9-2: Spain – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 9-3: Spain – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 9-4: Spain – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 9-5: Spain – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 9-6: Spain – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 9-7: Spain – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 9-8: Spain – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 10-1: United States – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 10-2: United States – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 10-3: United States – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 10-4: United States – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 10-5: United States – Multiple Sclerosis Injectables Patient Numbers (Thousand), 2011 – 2016
Figure 10-6: United States – Forecast for Multiple Sclerosis Injectables Patient Numbers (Thousand), 2017 – 2022
Figure 10-7: United States - Multiple Sclerosis Infusions Patient Numbers (Thousand), 2011 – 2016
Figure 10-8: United States – Forecast for Multiple Sclerosis Infusions Patient Numbers (Thousand), 2017 – 2022
Figure 10-9: United States - Multiple Sclerosis Orals Patient Numbers (Thousand), 2011 – 2016
Figure 10-10: United States – Forecast for Multiple Sclerosis Orals Patient Numbers (Thousand), 2017 – 2022
Figure 10-11: United States – Multiple Sclerosis Unmet Market (Billion US$), 2011 – 2016
Figure 10-12: United States – Forecast for Multiple Sclerosis Unmet Market (Billion US$), 2017 – 2022
Figure 10-13: United States – Multiple Sclerosis Market (Billion US$), 2011 – 2016
Figure 10-14: United States – Forecast for Multiple Sclerosis Market (Billion US$), 2017 – 2022
Figure 10-15: United States – Multiple Sclerosis Injectables Market (Million US$), 2011 – 2016
Figure 10-16: United States – Forecast for Multiple Sclerosis Injectables Market (Million US$), 2017 – 2022
Figure 10-17: United States – Multiple Sclerosis Infusions Market (Million US$), 2011 – 2016
Figure 10-18: United States – Forecast for Multiple Sclerosis Infusions Market (Million US$), 2017 – 2022
Figure 10-19: United States – Multiple Sclerosis Orals Market (Million US$), 2011 – 2016
Figure 10-20: United States – Forecast for Multiple Sclerosis Orals Market (Million US$), 2017 – 2022
Figure 12-1: Europe - Number of Neurologists per 100,000 Specialized in MS vs. Percent of MS Population Receiving DMDs, 2013

List Of Tables

LIST OF TABLES

Table 11 1: Europe - Reimbursements for Disease Modifying Drugs (DMDs), 2013